HC Wainwright & Co. Maintains Neutral on Sage Therapeutics, Lowers Price Target to $27
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Douglas Tsao has maintained a Neutral rating on Sage Therapeutics (NASDAQ:SAGE) and lowered the price target from $50 to $27.
August 08, 2023 | 10:12 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Sage Therapeutics' price target has been lowered from $50 to $27 by HC Wainwright & Co., while maintaining a Neutral rating.
The lowering of the price target for Sage Therapeutics by HC Wainwright & Co. indicates a less optimistic outlook for the company's stock in the short term. This could potentially lead to a decrease in the stock's price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100